“My practice is personalised and evidence-based. I view every patient almost like a friend or relative where we give the utmost care.”
Dr Daniel Chan Boon Yeow
Dr Chan graduated with the distinction of honours from National University of Singapore (NUS) School of Medicine in 2000. He was further trained in internal medicine and obtained the Member of the Royal College of Physicians; MRCP (UK) in 2004. He received his medical oncology specialist training with the National University Cancer Institute of Singapore. He finished his final year of fellowship in the USA at the University of California, Los Angeles (UCLA) and Cedars- Sinai Medical Centre. He honed his medical oncology clinical expertise at UCLA and Cedars-Sinai with Dr Ronald Natale (lung cancer), Dr Michael Lill (lymphoma), Dr Charles Forscher (sarcoma) and Dr Albert Lai (neuro-oncology) under an endowment grant from the National University Hospital of Singapore. He also pursued research in the laboratory of world-famous haematologist-oncologist Professor Phillip Koeffler under a National Medical Research Council Overseas Fellowship.
Upon his return, he was a consultant in medical oncology at the National University Cancer Institute Singapore and director of undergraduate education (medical oncology) at the National University of Singapore. He was also actively involved in cancer research at the Cancer Science Institute Singapore and held a new investigator grant from the NMRC on triple negative breast cancer.
He was the first in South Asia to use the PD-1 inhibitor immunotherapy drug (Pembrolizumab) in clinical practice in October 2014.
Dr Daniel Chan accepts referrals for all cancer types, with a special clinical interest in breast cancer, colon cancer, lung cancer, lymphoma and sarcoma.
Affiliations & Memberships
- American Society of Clinical Oncology (ASCO)
- International Association for the Study of Lung Cancer (IASLC)
- Connective Tissue Oncology Society (CTOS) of USA.
30 March 2020 – The Straits Times: Lung cancer in young people
EGFR Mutation Detection in Plasma Cell-free DNA Correlates with Clinical Outcomes in Non-Small Cell Lung Cancer. J. Shi…Daniel Chan…M. Tan. Annals of Oncology 2017; 28:5: v460-v496.
Short course pembrolizumab in complete responders with advanced non-small cell lung cancer. Daniel Chan. J Clin Oncol 2017; 35; abstr e20537.
Genomic and Functional Characterizations of Phosphodiesterase 4D in Human Cancers. D Lin,…Daniel Chan, HP Koeffler. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(15):6109-6114.
A study on the prevalence of Her2 Genetic Heterogeneity and its impact on survival. J Ho, SC Lee, Daniel Chan, ES Koay. J Clin Oncol. 2013; 31: abstr 586.
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Daniel Chan, WL Yeo, M Tiemsim-Cordero M, et al. Invest New Drugs. 2010; 28(6): 859-65.